0001209191-23-028993.txt : 20230512
0001209191-23-028993.hdr.sgml : 20230512
20230512160620
ACCESSION NUMBER: 0001209191-23-028993
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230510
FILED AS OF DATE: 20230512
DATE AS OF CHANGE: 20230512
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Calvin Sandra
CENTRAL INDEX KEY: 0001882909
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 23915634
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTER DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-05-10
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001882909
Calvin Sandra
C/O TRAVERE THERAPEUTICS, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
0
1
0
0
SVP, Chief Accounting Officer
1
Common Stock
2023-05-10
4
S
0
436
16.59
D
42369
D
Common Stock
2023-05-11
4
S
0
122
16.12
D
42247
D
Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.
The sales reported in this Form 4 were made pursuant to a written plan adopted by the Reporting Person on September 14, 2022 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2023-05-12